Scientific Report 2010 Leung (801.15 kB)

Key Publications

Ahmad I, Morton J, Singh BL, Radulescu SM, Ridgway RA, Patel S, Woodgett J, D, Winton DL, Taketo MM, Wu XR Leung HY, Sansom OJ (2010). β-catenin activation synergises with PTEN loss to cause bladder cancer formation. Oncogene 30, 178-89.

Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, Robson CN, Kozielski F and Leung HY (2010). Docetaxel resistant prostate cancer cells remain sensitive to S-trityl L-cysteine (STLC) mediated Eg5 inhibition. Mol Cancer Therapeutics 9, 1730-9.

McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P, Leung HY (2008). Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 27, 2978-88.

McKie AB, Douglas DA, Olijislagers S, Graham J, Heer R, Robson CN and Leung HY (2005). Epigenetic inactivation of the human Sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 24, 2166-74.

Gnanapragasam VJ, Neal DE, Robson CN and Leung HY (2002). Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene 21, 5069-80.

Education and qualifications
1986: MB ChB, University of Aberdeen
1990: FRCS (Glas) , Royal College of Physicians and Surgeons of Glasgow
1994: PhD, University of London, Supervisor Nick Lemoine
1997: FRCS (Urol), Royal Colleges of Surgeons (UK & Ireland)

Appointments
2006-present: Professor of Urology and Surgical Oncology, University of Glasgow; Group leader, Beatson Institute for Cancer Research; Consultant Urological Surgeon, NHS Greater Glasgow and Clyde
2002-2006: Professor of Urological Oncology, University of Newcastle upon Tyne
1999-2002: Senior Lecturer, University of Newcastle upon Tyne
1995-1998: Clinical Lecturer, University of Newcastle upon Tyne
1990-1994: Clinical Research Fellow, Imperial Cancer Research Fund
1987-1989: Surgical Registrar, Birmingham Rotation

Honours and awards
The Karl Storz Harold Hopkins Golden Telescope Award, British Association of Urological Surgeons, 2008
Founding member of the Northern Institute for Cancer Research, University of Newcastle upon Tyne

2011
Ramsay AK, McCracken SRC, Soofi M, Morland R, Fleming J, Yu AX, Machesky L, Nixon C, Edwards DE, Nuttall RK, Seywright M, Keller E, Leung HY (2011). ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer 104, 664-72.

Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, Wu XR, Leung HY, Sansom OJ (2011). Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death Dis. 2, e124.

Ahmad I, Singh LB, Foth M, Morris CA, Taketo MM, Wu XR, Leung HY, Sansom OJ, Iwata T (2011). K-Ras and {beta}-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis Model Mech. 4, 548-55.

de Brito LR, Batey MA, Zhao Y, Squires MS, Maitland H, Leung HY, Hall AG, Jackson G, Newell DR, Irving JA (2011). Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma. Leuk Res. 2011 Feb 10. [Epub ahead of print].

Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, Smith GC, Leung HY, Curtin NJ, Robson CN (2011). Targeting the DNA double strand break repair machinery in prostate cancer. PLoS One 6, e20311.

2010
Tan SS, Ahmad I, Bennett HL, Singh L, Nixon C, Seywright M, Barnetson RJ, Edwards J, Leung HY (2010). GRP78 up-Regulation is associated with AR status, Hsp70-Hsp90 client proteins and castrate resistant prostate cancer. J Pathol. 223, 81-7.

Bennett HL, Fleming J, O’Prey J, Ryan KM, Leung HY (2010). Androgens modulate autophagy and cell death via regulation of the ER chaperone Grp78/BiP in prostate cancer cells. Cell Death Disease 1, e72.

Dudderidge TJ, Kelly JD, Wollenschlaeger A, Okoturo O, Prevost T, Robson W, Leung HY, Stoeber K, Williams GH (2010). Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments. Br J Cancer 103, 701-7.

Ahmad I, Morton J, Singh BL, Radulescu SM, Ridgway RA, Patel S, Woodgett J, D, Winton DL, Taketo MM, Wu XR Leung HY, Sansom OJ (2010). β-catenin activation synergises with PTEN loss to cause bladder cancer formation. Oncogene 30, 178-89.

Watson AJ, Sabharwal A, Thorncroft M, McGown G, Kerr R, Bojanic S, Soonawalla Z, King A, Miller A, Waller S, Leung HY, Margison GP, Middleton MR (2010). Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib. Clin Cancer Res. 16, 743-9.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group (2010). Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 362, 1192-202 (HYL included as named collaborator).

Macefield RC, Metcalfe C, Lane JA, Donovan JL, Avery KN, Blazeby JM, Down L, Neal DE, Hamdy FC, Vedhara K; ProtecT Study Group. (2010). Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. Br J Cancer 102, 1335-40 (HYL included as named collaborator).

Heer R, Clarke N, Rigas AC, Cheek TR, Pickard R, Leung HY (2010). Phenotypic modulation of human urinary tract stroma-derived fibroblasts by transforming growth factor beta3. Urology 76, 509.e13-20.

Eeles RA, Kote-Jarai Z, Al Olama AA, et al; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF (2009). Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 41, 1116-21 (HYL included as named collaborator).

Al Olama AA, Kote-Jarai Z, Giles GG, et al; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, et al. (2009). Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet. 41, 1058-60 (HYL included as named collaborator).

Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, Barnetson R, Robson CN, Kozielski F, Leung HY (2010). Docetaxel resistant prostate cancer cells remain sensitive to S-trityl L-cysteine (STLC) mediated Eg5 inhibition. Mol Cancer Therapeutics 9, 1730-9.

2009
Nelson AW, Ahmad I, Pickard R, Leung HY (2009). The new BAUS Section of Academic Urology: A survey of the urological community. British Journal of Medical and Surgical Urology 2, 147-53.

Darby S, Murphy T, Thomas H, Robson CN, Leung HY, Mathers ME, Gnanapragasam VJ (2009). Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. Br J Cancer 101, 1891-9.

Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS, James ND (2009). Virus Directed Enzyme Prodrug Therapy Using An Adenovirus Expressing Nitroreductase With CB1954: A Phase I/II Clinical Trial In Localized Prostate Cancer. Mol Ther. 17, 1292-9.

Rajan P, Dalgliesh C, Bourgeois CF, Heiner M, Emami K, Clark EL, Bindereif A, Stevenin J, Robson CN, Leung HY, Elliott DJ (2009). Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 Nuclear Bodies. BMC Cell Biol. 10, 82.

Stevenson R, Ingram A, Leung H, McMillan DC, Graham D (2009). Quantitative SERRS immunoassay for the detection of human PSA. Analyst 134, 842-4.

Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J (2009). SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res. 15, 3540-9.

Thirkettle HJ, Girling J, Warren AY, Mills IG, Sahadevan K, Leung H, Hamdy F, Whitaker HC, Neal DE (2009). LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. Clin Cancer Res. 15, 3003-13.

Carling PJ, Elliott DJ, Robson CN, Leung HY, Rajan P (2009). Targeting alternative splicing in prostate oncology. Discov Med. 8, 74-80.

Rajan P, Elliott DJ, Robson CN, Leung HY (2009). Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol. 6, 454-60.

Ramsay AK, Leung HY (2009). Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clin Sci (Lond). 117, 209-28.

2008
McCracken SR, Ramsay A, Heer R, Mathers ME, Jenkins BL, Edwards J, Robson CN, Marquez R, Cohen P, Leung HY (2008). Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene 27, 2978-88.

Dovedi SJ, Kirby JA, Davies BR, Leung H, Kelly JD (2008). Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. Eur Urol. 54, 621-30.

Rajan P, Gaughan L, Dalgliesh C, El-Sherif A, Robson CN, Leung HY, Elliott DJ (2008). The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. J Path 215, 67-77.

Whitaker HC, Girling J, Warren AY, Leung HY, Mills IG, Neal DE (2008). Alterations in beta-catenin expression and localization in prostate cancer. Prostate 68, 1196-205.

Clark EL, Coulson A, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN (2008). The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res. 68, 7938-46.

Rogerson L, Darby S, Jabbar T, Mathers ME, Leung HY, Robson CN, Sahadevan K, O'Toole K, Gnanapragasam VJ (2008). Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int. 102, 364-70.

Ahmad I, Sansom OJ, Leung HY (2008). Advances in mouse models of prostate cancer. Expert Rev Mol Med. 10, e16.

Post-doc: Rachana Patel, Michelle Welsh

Clinical Lecturers: Imran Ahmad, Prabhakar Rajan

Scientific Officer: Janis Fleming

PhD Student: Meiling Gao